Australia's most trusted
source of pharma news
Sunday, 23 February 2025
Posted 21 February 2025 AM
Australia’s medicines regulator has kicked off the year accepting a raft of drug applications for review that could see seven innovative medicines plus eight new indications for existing treatments arrive by the end of the year.
Among the newcomers is GSK’s highly anticipated Blenrep, a first-in-class anti-BCMA therapy approved by the FDA back in 2020 for multiple myeloma.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.